Article R5222-4 of the French Public Health Code
The Director General of the Agence nationale de sécurité du médicament et des produits de santé shall carry out his duties relating to reactovigilance under the conditions defined in Article R. 5311-2. He shall ensure compliance with the monitoring procedures organised by this chapter. When informed of an incident or risk of incident, or of the recall of an in vitro diagnostic medical device, the Director General will arrange for…